Cytori Therapeutics Publishes Review on Potential of Adipose Stem Cells to Treat Cardiovascular Disease in Nature Clinical Practice
Wednesday March 1, 9:30 am ET
SAN DIEGO--(BUSINESS WIRE)--March 1, 2006--Cytori Therapeutics, Inc. (NASDAQ:CYTX - News; Frankfurt:XMPA - News) announced today the publication of a summary of peer-reviewed research, authored by Cytori scientists, on the potential of adipose stem cells in cardiac cell therapy. The article, titled "Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes," appears in the Cardiovascular Medicine Supplement of Nature Clinical Practice, March 3, 2006, Volume 3, Supplement 1, and is available online this week (www.nature.com/clinicalpractice).
ADVERTISEMENT
"Publication of this review demonstrates the excitement within the scientific community about the potential of adipose stem cells, in particular the clinical applications in cardiovascular disease," said Marc H. Hedrick, M.D., President, Cytori Therapeutics. "The article illustrates that we and others have reported consistent findings regarding the mechanisms by which adipose stem cells improve cardiac function. Based on the abundance of data such as this, we look forward to initiating studies this year to evaluate adipose stem cells in a clinical setting for cardiac therapy."
The review highlights the proposed mechanisms by which adipose stem cells contribute to the repair of damaged cardiac muscle, specifically the angiogenic effects and the prevention of cell death as primary mechanisms as well as differentiation into new cardiac muscle. Additionally, the article points to the ability to obtain a high yield of adipose stem cells from patients in real-time with relative ease compared to bone marrow and other adult stem cell sources. The functional benefit has been observed in multiple preclinical studies.
About Cytori Therapeutics
Cytori Therapeutics, Inc. (NASDAQ:CYTX - News; Frankfurt:XMPA - News) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics' future operating results and financial position. Such statements are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially. Some of these risks and uncertainties are described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2004, and subsequent SEC filings, which are available through the Company's web site. Cytori Therapeutics assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made |
